Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 368

1.

Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report.

Michot JM, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, Balleyguier C, Besse B, Marabelle A, Netzer F, Merad M, Robert C, Barlesi F, Gachot B, Stoclin A.

Ann Oncol. 2020 Apr 2. pii: S0923-7534(20)36387-0. doi: 10.1016/j.annonc.2020.03.300. [Epub ahead of print] No abstract available.

PMID:
32247642
2.

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.

Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L.

Lancet Oncol. 2020 Mar 27. pii: S1470-2045(20)30068-1. doi: 10.1016/S1470-2045(20)30068-1. [Epub ahead of print]

PMID:
32224306
3.

Brief report: High prevalence of somatic oncogenic driver alterations in non-small cell lung cancer patients with Li-Fraumeni Syndrome.

Mezquita L, Jove M, Nadal E, Kfoury M, Morán T, Ricordel C, Dhooge M, Tlemsani C, Léna H, Teulé A, Álvarez JV, Raimbourg J, Hiret S, Pharma LL, Menéndez M, Saldaña J, Brunet J, Lianes P, Coupier I, Auclin E, Recondo G, Friboulet L, Adam J, Green E, Planchard D, Frébourg T, Capellà G, Rouleau E, Lázaro C, Caron O, Besse B.

J Thorac Oncol. 2020 Mar 13. pii: S1556-0864(20)30197-0. doi: 10.1016/j.jtho.2020.03.005. [Epub ahead of print]

PMID:
32179180
4.

The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study.

Michot JM, Lappara A, Le Pavec J, Simonaggio A, Collins M, De Martin E, Danlos FX, Ammari S, Cauquil C, Ederhy S, Barreau E, Belkhir R, Berdelou A, Lazarovici J, Chanson P, Izzedine H, Seferian A, Le Pajolec C, Baldini C, Martin-Romano P, Mariette X, Robert C, Besse B, Hollebecque A, Varga A, Laghouati S, Mateus C, Voisin AL, Soria JC, Massard C, Marabelle A, Champiat S, Lambotte O.

Eur J Cancer. 2020 Mar 12;130:39-50. doi: 10.1016/j.ejca.2020.02.010. [Epub ahead of print]

PMID:
32172197
5.

Randomized phase II trial evaluating treatment with EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.

Mazieres J, Barlesi F, Rouquette I, Molinier O, Besse B, Monnet I, Audigier-Valette C, Toffart AC, Renault PA, Fraboulet S, Hiret S, Mennecier B, Debieuvre D, Westeel V, Masson P, Madroszyk-Flandin A, Pichon E, Cortot AB, Amour E, Morin F, Zalcman G, Moro-Sibilot D, Souquet PJ.

Clin Cancer Res. 2020 Mar 6. pii: clincanres.3056.2019. doi: 10.1158/1078-0432.CCR-19-3056. [Epub ahead of print]

PMID:
32144133
6.

Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.

Baldini C, Martin Romano P, Voisin AL, Danlos FX, Champiat S, Laghouati S, Kfoury M, Vincent H, Postel-Vinay S, Varga A, Vuagnat P, Ribrag V, Mezquita L, Besse B, Hollebecque A, Lambotte O, Michot JM, Soria JC, Massard C, Marabelle A.

Eur J Cancer. 2020 Apr;129:71-79. doi: 10.1016/j.ejca.2020.01.013. Epub 2020 Mar 3.

PMID:
32143106
7.

EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer.

Lindsay CR, Blackhall FH, Carmel A, Gazzaniga P, Groen HJM, Krebs MG, Muinelo-Romay L, Pantel K, Rossi E, Terstappen L, Wikman H, Soria JC, Farace FF, Renehan A, Dive C, Besse B, Michiels S.

Ann Oncol. 2019 Apr;30 Suppl 2:ii7. doi: 10.1093/annonc/mdz073. No abstract available.

8.

Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts).

Ferrara R, Naigeon M, Auclin E, Duchemann B, Cassard L, Medhi JJ, Boselli L, Grivel J, Desnoyer A, Mezquita L, Hendriks L, Planchard D, Caramella C, Remon-Masip J, Sangaletti S, Garassino MC, Besse B, Chaput N.

Ann Oncol. 2019 Apr;30 Suppl 2:ii7-ii8. doi: 10.1093/annonc/mdz073.002. No abstract available.

9.

Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001.

Paz-Ares L, Doebele RC, Farago AF, Liu SV, Chawla SP, Tosi D, Blakely CM, Krauss JC, Sigal D, Bazhenova L, John T, Besse B, Wolf J, Seto T, Chow-Maneval E, Ye C, Simmons B, Demetri GD.

Ann Oncol. 2019 Apr;30 Suppl 2:ii48-ii49. doi: 10.1093/annonc/mdz063.011. No abstract available.

10.

Plasma circulating tumor DNA analysis (ctDNA) for molecular alteration detection in advanced non-small cell lung cancer (NSCLC) patients (pts) with isolated central nervous system (CNS) metastases (mts).

Aldea M, Hendriks L, Mezquita L, Remon-Masip J, Planchard D, Jovelet C, Benitez JC, Gazzah A, Naltet C, Lavaud P, Lacroix L, Howarth K, Morris C, Green E, Nicotra C, Besse B.

Ann Oncol. 2019 Apr;30 Suppl 2:ii48. doi: 10.1093/annonc/mdz063.008. No abstract available.

11.

Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.

Besse B, Garrido P, Cortot AB, Johnson M, Murakami H, Gazzah A, Gil M, Bennouna J.

Lung Cancer. 2020 Apr;142:63-69. doi: 10.1016/j.lungcan.2020.02.003. Epub 2020 Feb 19.

PMID:
32114283
12.

Applicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials.

Varga A, Bernard-Tessier A, Auclin E, Mezquita Pérez L, Baldini C, Planchard D, Marabelle A, Hollebecque A, Besse B, Massard C.

Ann Oncol. 2019 Feb;30 Suppl 1:i2. doi: 10.1093/annonc/mdz027.001. Epub 2020 Jan 8. No abstract available.

13.

CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?

Benitez JC, Remon J, Besse B.

Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S464-S467. doi: 10.21037/tlcr.2019.12.26. No abstract available.

14.

[Role of immunotherapy in locally advanced non-small cell lung cancer].

Levy A, Doyen J, Botticella A, Bourdais R, Achkar S, Giraud P, Du C, Naltet C, Lavaud P, Besse B, Pradère P, Mercier O, Caramella C, Planchard D, Deutsch E, Le Péchoux C.

Cancer Radiother. 2020 Feb;24(1):67-72. doi: 10.1016/j.canrad.2019.09.007. Epub 2020 Feb 6. French.

PMID:
32037126
15.

One or Two Immune Checkpoint Inhibitors?

Robert C, Lanoy E, Besse B.

Cancer Cell. 2019 Dec 9;36(6):579-581. doi: 10.1016/j.ccell.2019.11.005.

PMID:
31951559
16.

Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in France.

Noël N, Le Roy A, Hot A, Saadoun D, Lazaro E, Lévesque H, Le Gouellec N, Meaux-Ruault N, Nguyen T, Costedoat-Chalumeau N, Amieux B, Fontana A, De Gennes C, Fulpin J, Thomas PA, Bluthgen MV, Besse B, Lambotte O.

Autoimmun Rev. 2020 Mar;19(3):102464. doi: 10.1016/j.autrev.2020.102464. Epub 2020 Jan 7.

PMID:
31917264
17.

Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression.

Aldea M, Hendriks L, Mezquita L, Jovelet C, Planchard D, Auclin E, Remon J, Howarth K, Benitez JC, Gazzah A, Lavaud P, Naltet C, Lacroix L, de Kievit F, Morris C, Green E, Ngo-Camus M, Rouleau E, Massard C, Caramella C, Friboulet L, Besse B.

J Thorac Oncol. 2020 Mar;15(3):383-391. doi: 10.1016/j.jtho.2019.11.024. Epub 2019 Dec 13.

PMID:
31843682
18.

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators.

Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11. Erratum in: Lancet Oncol. 2020 Feb;21(2):e70.

PMID:
31838007
19.

Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1.

Rouquette I, Taranchon-Clermont E, Gilhodes J, Bluthgen MV, Perallon R, Chalabreysse L, De Muret A, Hofman V, Marx A, Parrens M, Secq V, Thomas de Montpreville V, Galateau-Salle F, Brousset P, Milia J, Girard N, Besse B, Molina TJ, Mazières J.

Biomark Res. 2019 Dec 4;7:28. doi: 10.1186/s40364-019-0177-8. eCollection 2019.

20.

Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77].

Putora PM, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadiuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O' Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman BJ.

Radiother Oncol. 2019 Dec;141:332. doi: 10.1016/j.radonc.2019.10.006. No abstract available.

PMID:
31810511
21.

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.

Park W, Mezquita L, Okabe N, Chae YK, Kwon D, Saravia D, Auclin E, Planchard D, Caramella C, Ferrara R, Agte S, Oh M, Mudad R, Jahanzeb M, Suzuki H, Besse B, Lopes G.

Br J Cancer. 2020 Feb;122(3):340-347. doi: 10.1038/s41416-019-0643-y. Epub 2019 Nov 25.

PMID:
31761899
22.

Oligometastatic non-small cell lung cancer (NSCLC): Does number of metastasis matter?

Giaj-Levra N, Giaj Levra M, Berghmans T, Novello S, Hendriks LE, Levy A, Besse B, Dingemans AC.

Lung Cancer. 2020 Jan;139:216-218. doi: 10.1016/j.lungcan.2019.11.005. Epub 2019 Nov 13. No abstract available.

PMID:
31761473
23.

Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?

Enrico D, Paci A, Chaput N, Karamouza E, Besse B.

Clin Cancer Res. 2020 Feb 15;26(4):787-792. doi: 10.1158/1078-0432.CCR-19-2337. Epub 2019 Nov 22.

PMID:
31757876
24.

Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.

Seban RD, Mezquita L, Berenbaum A, Dercle L, Botticella A, Le Pechoux C, Caramella C, Deutsch E, Grimaldi S, Adam J, Ammari S, Planchard D, Leboulleux S, Besse B.

Eur J Nucl Med Mol Imaging. 2020 May;47(5):1147-1157. doi: 10.1007/s00259-019-04615-x. Epub 2019 Nov 21.

PMID:
31754795
25.

Correction to: Focus on Recommendations for the Management of Non-small Cell Lung Cancer.

Lavaud P, Besse B, de Baere T, Deschamps F, Mussot S, Le Pechoux C, Caramella C, Mercier O, Mezquita L, Botticella A, Pradere P, Adam J, Planchard D, Tselikas L.

Cardiovasc Intervent Radiol. 2020 Jan;43(1):168. doi: 10.1007/s00270-019-02370-y.

PMID:
31690981
26.

EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease.

Levy A, Hendriks LEL, Berghmans T, Faivre-Finn C, GiajLevra M, GiajLevra N, Hasan B, Pochesci A, Girard N, Greillier L, Lantuéjoul S, Edwards J, O'Brien M, Reck M, Besse B, Novello S, Dingemans AC; EORTC Lung Cancer Group (EORTC LCG).

Eur J Cancer. 2019 Nov;122:109-114. doi: 10.1016/j.ejca.2019.09.012. Epub 2019 Oct 28.

PMID:
31671363
27.

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.

Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI.

Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25.

PMID:
31669155
28.

In Response to the Letter by Dr. Yang et al, Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Forcing on Organ-Specific irAEs and the Critical Role of Steroids.

Besse B, Remon J.

J Thorac Oncol. 2019 Nov;14(11):e260-e261. doi: 10.1016/j.jtho.2019.07.029. No abstract available.

PMID:
31668327
29.

Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion.

Hendriks LEL, Dooms C, Berghmans T, Novello S, Levy A, De Ruysscher D, Hasan B, Giaj Levra M, Giaj Levra N, Besse B, Vansteenkiste J, Dingemans AC; European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group.

Eur J Cancer. 2019 Dec;123:28-35. doi: 10.1016/j.ejca.2019.09.013. Epub 2019 Oct 23.

30.

A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.

Besse B, Barlesi F, Demedts I, Fuentes Pradera J, Robinet G, Gazzah A, Soldatenkova V, Frimodt-Moller B, Kim JS, Vansteenkiste J.

Lung Cancer. 2019 Nov;137:136-143. doi: 10.1016/j.lungcan.2019.09.002. Epub 2019 Sep 3.

PMID:
31586771
31.

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.

Recondo G, Mezquita L, Facchinetti F, Planchard D, Gazzah A, Bigot L, Rizvi AZ, Frias RL, Thiery JP, Scoazec JY, Sourisseau T, Howarth K, Deas O, Samofalova D, Galissant J, Tesson P, Braye F, Naltet C, Lavaud P, Mahjoubi L, Abou Lovergne A, Vassal G, Bahleda R, Hollebecque A, Nicotra C, Ngo-Camus M, Michiels S, Lacroix L, Richon C, Auger N, De Baere T, Tselikas L, Solary E, Angevin E, Eggermont AM, Andre F, Massard C, Olaussen KA, Soria JC, Besse B, Friboulet L.

Clin Cancer Res. 2020 Jan 1;26(1):242-255. doi: 10.1158/1078-0432.CCR-19-1104. Epub 2019 Oct 4.

PMID:
31585938
32.

Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey.

Levy A, Hendriks LEL, Le Péchoux C, Falk S, Besse B, Novello S, Dingemans AC, Hasan B, Reck M, Berghmans T, Faivre-Finn C; EORTC Lung Cancer Group (EORTC LCG).

Lung Cancer. 2019 Oct;136:145-147. doi: 10.1016/j.lungcan.2019.08.007. Epub 2019 Aug 13.

PMID:
31520867
33.

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.

Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, Glisson BS, Farago AF, Dowlati A, Rudin CM, Le Moulec S, Lally S, Yalamanchili S, Wolf J, Govindan R, Carbone DP.

Clin Cancer Res. 2019 Dec 1;25(23):6958-6966. doi: 10.1158/1078-0432.CCR-19-1133. Epub 2019 Sep 10.

34.

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration.

Mountzios G, Remon J, Novello S, Blais N, Califano R, Cufer T, Dingemans AM, Liu SV, Peled N, Pennell NA, Reck M, Rolfo C, Tan D, Vansteenkiste J, West H, Besse B.

Ann Oncol. 2019 Nov 1;30(11):1686-1688. doi: 10.1093/annonc/mdz295. No abstract available.

PMID:
31504132
35.

Letter to the Editor about Sorich et al.

Mezquita L, Auclin E, Besse B.

J Thorac Oncol. 2019 Sep;14(9):e209. doi: 10.1016/j.jtho.2019.05.022. No abstract available.

PMID:
31445741
36.

Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer.

Pailler E, Faugeroux V, Oulhen M, Mezquita L, Laporte M, Honoré A, Lecluse Y, Queffelec P, NgoCamus M, Nicotra C, Remon J, Lacroix L, Planchard D, Friboulet L, Besse B, Farace F.

Clin Cancer Res. 2019 Nov 15;25(22):6671-6682. doi: 10.1158/1078-0432.CCR-19-1176. Epub 2019 Aug 22.

PMID:
31439588
37.

Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?

Remon J, Hendriks L, Aspeslagh S, Besse B.

J Thorac Oncol. 2019 Oct;14(10):1701-1703. doi: 10.1016/j.jtho.2019.07.004. Epub 2019 Aug 13. No abstract available.

PMID:
31420287
38.

Treatment duration of checkpoint inhibitors for NSCLC.

Remon J, Menis J, Aspeslagh S, Besse B.

Lancet Respir Med. 2019 Oct;7(10):835-837. doi: 10.1016/S2213-2600(19)30192-4. Epub 2019 Aug 7. No abstract available.

PMID:
31401050
39.

Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report.

Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, Giaj-Levra M, Giaj-Levra N, Girard N, Greillier L, Lantuéjoul S, Edwards J, O'Brien M, Reck M, Smit EF, Van Schil P, Postmus PE, Ramella S, Lievens Y, Gaga M, Peled N, Scagliotti GV, Senan S, Paz-Ares L, Guckenberger M, McDonald F, Ekman S, Cufer T, Gietema H, Infante M, Dziadziuszko R, Peters S, Porta RR, Vansteenkiste J, Dooms C, de Ruysscher D, Besse B, Novello S.

J Thorac Oncol. 2019 Dec;14(12):2109-2119. doi: 10.1016/j.jtho.2019.07.025. Epub 2019 Aug 6.

PMID:
31398540
40.

Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?

Rassy E, Mezquita L, Remon J, Besse B.

Immunotherapy. 2019 Sep;11(13):1149-1160. doi: 10.2217/imt-2019-0071. Epub 2019 Jul 30.

PMID:
31361172
41.

Hepatic Intra-Arterial Chemotherapy With Immunotherapy in NSCLC.

Benitez JC, Mezquita L, Colle R, Tselikas L, Botticella A, Caramella C, Besse B.

J Thorac Oncol. 2019 Oct;14(10):e215-e216. doi: 10.1016/j.jtho.2019.07.001. Epub 2019 Jul 11. No abstract available.

PMID:
31302233
42.

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC.

Bauer TM, Besse B, Martinez-Marti A, Trigo JM, Moreno V, Garrido P, Ferron-Brady G, Wu Y, Park J, Collingwood T, Kruger RG, Mohammad HP, Ballas MS, Dhar A, Govindan R.

J Thorac Oncol. 2019 Oct;14(10):1828-1838. doi: 10.1016/j.jtho.2019.06.021. Epub 2019 Jun 28.

43.

EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer.

Lindsay CR, Blackhall FH, Carmel A, Fernandez-Gutierrez F, Gazzaniga P, Groen HJM, Hiltermann TJN, Krebs MG, Loges S, López-López R, Muinelo-Romay L, Pantel K, Priest L, Riethdorf S, Rossi E, Terstappen L, Wikman H, Soria JC, Farace F, Renehan A, Dive C, Besse B, Michiels S.

Eur J Cancer. 2019 Aug;117:60-68. doi: 10.1016/j.ejca.2019.04.019. Epub 2019 Jun 27.

44.

Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial.

Montalescot G, Brotons C, Cosyns B, Crijns HJ, D'Angelo A, Drouet L, Eberli F, Lane DA, Besse B, Chan A, Vicaut E, Darius H; AEGEAN Study Investigators.

Am J Cardiovasc Drugs. 2020 Feb;20(1):61-71. doi: 10.1007/s40256-019-00356-2.

45.

Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.

Hendriks LEL, Bootsma G, Mourlanette J, Henon C, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Duchemann B, Cousin S, le Pechoux C, Botticella A, De Ruysscher D, Dingemans AC, Besse B.

Eur J Cancer. 2019 Jul;116:182-189. doi: 10.1016/j.ejca.2019.05.019. Epub 2019 Jun 13.

PMID:
31203193
46.

Defining Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Systematic Review.

Giaj-Levra N, Giaj-Levra M, Durieux V, Novello S, Besse B, Hasan B, Hendriks LE, Levy A, Dingemans AC, Berghmans T; European Organization for Research and Treatment of Cancer-Lung Cancer Group.

J Thorac Oncol. 2019 Dec;14(12):2053-2061. doi: 10.1016/j.jtho.2019.05.037. Epub 2019 Jun 11. Review.

PMID:
31195177
47.

Multiple colic intussusceptions.

Tzedakis S, Flacs M, Besse B, Goere D.

Clin Case Rep. 2019 May 11;7(6):1265-1266. doi: 10.1002/ccr3.2181. eCollection 2019 Jun.

48.

Hyperprogression during immunotherapy: do we really want to know?

Champiat S, Besse B, Marabelle A.

Ann Oncol. 2019 Jul 1;30(7):1028-1031. doi: 10.1093/annonc/mdz184. No abstract available.

PMID:
31173063
49.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez-Marti A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O.

Ann Oncol. 2019 Aug 1;30(8):1321-1328. doi: 10.1093/annonc/mdz167.

PMID:
31125062
50.

Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.

Flippot R, Biondani P, Auclin E, Xiao D, Hendriks L, Le Rhun E, Leduc C, Beau-Faller M, Gervais R, Remon J, Adam J, Planchard D, Lavaud P, Naltet C, Caramella C, Le Pechoux C, Lacroix L, Gazzah A, Mezquita L, Besse B.

J Thorac Oncol. 2019 Aug;14(8):1400-1407. doi: 10.1016/j.jtho.2019.05.007. Epub 2019 May 18.

PMID:
31108248

Supplemental Content

Support Center